DiaMedica reports Q1 2022 cash burn of $3.9M; ReMEDy2 stroke trial sites more than double

DiaMedica Therapeutics Inc.

Cash & investments $41M at March 31 (Dec 31: $45.1M); working capital $40.7M; cash runway into 2024.
Net cash used in ops $3.9M (Q1 2021: $4.3M); R&D exp $2.0M (-$0.4M); G&A exp $1.6M (+$0.4M).
ReMEDy2 stroke trial active sites more than doubled to 9; slower enrollment due to COVID staffing & discharge logistics.
REDUX CKD trial fully enrolled (79 patients); last visit in March 2022; final analysis ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.